Clinigen Limited (‘Clinigen’ or the ‘Company’), the global pharmaceutical services company, has agreed to acquire Drug Safety Navigator Inc. (‘DSN’), a specialist pharmacovigilance service provider based in the US. This acquisition enables Clinigen to add vital pharmacovigilance capabilities to its leading pharma services offering for pharmaceutical and biotech clients. Establishing and maintaining effective pharmacovigilance is increasingly challenging in a globally diverse and complex regulatory environment. DSN provides a suite of global pharmacovigilance (‘PV’) services for clients, including adverse event reporting and medical monitoring as well as call centre support and PV system audits, for both clinical and post-marketed medical products.
Read the full article: Clinigen Adds Pharmacovigilance Capabilities with Acquisition of Drug Safety Navigator //
Source: https://www.globenewswire.com/news-release/2022/11/29/2563654/0/en/Clinigen-adds-pharmacovigilance-capabilities-with-acquisition-of-Drug-Safety-Navigator.html